Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Future potential targets of antibody-drug conjugates in breast cancer.
Corti C, Boscolo Bielo L, Schianca AC, Salimbeni BT, Criscitiello C, Curigliano G. Corti C, et al. Among authors: salimbeni bt. Breast. 2023 Jun;69:312-322. doi: 10.1016/j.breast.2023.03.007. Epub 2023 Mar 24. Breast. 2023. PMID: 36996620 Free PMC article. Review.
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini Rocco E, Curigliano G, Fusco N, Malapelle U. Venetis K, et al. Among authors: taurelli salimbeni b. Cancer Treat Rev. 2023 Dec;121:102642. doi: 10.1016/j.ctrv.2023.102642. Epub 2023 Oct 13. Cancer Treat Rev. 2023. PMID: 37864956 Review.
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.
Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli MA, Trapani D, Pescia C, Fusco N, Curigliano G, Criscitiello C. Antonarelli G, et al. Among authors: taurelli salimbeni b. Crit Rev Oncol Hematol. 2023 Dec;192:104148. doi: 10.1016/j.critrevonc.2023.104148. Epub 2023 Oct 1. Crit Rev Oncol Hematol. 2023. PMID: 37783318 Review.
PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. Morganti S, et al. Among authors: taurelli salimbeni b. JAMA Oncol. 2024 Mar 21. doi: 10.1001/jamaoncol.2023.7322. Online ahead of print. JAMA Oncol. 2024. PMID: 38512229
15 results